Michael Jon Brown, Executive Vice President and Chief Legal Compliance Officer of DexCom Inc (NASDAQ:DXCM), filed a Form 4 on August 17, 2026, reporting the sale of 1,700 shares of common stock on August 14, 2026, pursuant to a pre-established 10b5-1 trading plan.

Key Highlights

  • Shares sold: 1,700 shares of DexCom common stock disposed of on August 14, 2026.
  • Sale price: $91.93 per share.
  • Beneficial ownership after transaction: 102,953 shares, held directly.
  • Trading plan origin: The sale was made under a 10b5-1 Plan adopted by Mr. Brown on November 26, 2025.
  • Unvested RSUs included: 74,753 unvested restricted stock units are included in the post-transaction ownership figure.
  • Filing signed: Jereme M. Sylvain, as Attorney-in-Fact for Michael Jon Brown, signed on August 17, 2026.

DexCom EVP Brown's Share Sale: Transaction Details and Ownership Breakdown

According to the Form 4 filed with the SEC, Michael Jon Brown, identified as EVP Chief Legal Compliance Officer of DexCom Inc, sold 1,700 shares of common stock at $91.93 per share on August 14, 2026. The filing states the transaction was carried out under a Rule 10b5-1 plan that Mr. Brown adopted on November 26, 2025, described in the filing as a plan that "allows the orderly disposition of shares owned by Mr. Brown."

Following the transaction, Mr. Brown directly holds 102,953 shares of DexCom common stock, according to the filing. The filing discloses that 74,753 of those shares are unvested restricted stock units. Of those RSUs, 39,019 were granted on March 8, 2026, and vest through March 8, 2029; 19,948 were granted on March 8, 2025, and vest through March 8, 2028; 8,549 were granted on March 8, 2025, and vest through March 8, 2027; and 7,237 were granted on March 8, 2024, and vest through March 8, 2027.

No derivative securities transactions were reported in Table II of the filing. The transaction was coded "S" (open-market sale), and the filing was submitted by one reporting person. The box indicating the transaction was made pursuant to a contract, instruction, or written plan satisfying Rule 10b5-1(c) affirmative defense conditions was checked on the form.

What Was Disclosed

DexCom EVP and Chief Legal Compliance Officer Michael Jon Brown reported the sale of 1,700 shares at $91.93 each on August 14, 2026, under a 10b5-1 plan adopted November 26, 2025, leaving him with direct beneficial ownership of 102,953 shares, including 74,753 unvested RSUs.